Compile Data Set for Download or QSAR
Report error Found 88 Enz. Inhib. hit(s) with all data for entry = 9737
TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485113(US10934304, Example 34)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485112(US10934304, Example 33)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485111(US10934304, Example 32)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485110(US10934304, Example 31)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485109(US10934304, Example 30)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485108(US10934304, Example 29)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485107(US10934304, Example 28)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485106(US10934304, Example 27)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485105(US10934304, Example 26)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485104(US10934304, Example 25)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485103(US10934304, Example 24)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485102(US10934304, Example 23)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485101(US10934304, Example 22)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485100(US10934304, Example 21 | US10934304, Example 70)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485099(US10934304, Example 20)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485098(US10934304, Example 19)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485129(US10934304, Example 50)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485128(US10934304, Example 49)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485127(US10934304, Example 48)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485126(US10934304, Example 47)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485125(US10934304, Example 46)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485124(US10934304, Example 45)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485123(US10934304, Example 44)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485122(US10934304, Example 43)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485120(US10934304, Example 41)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485119(US10934304, Example 40)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485117(US10934304, Example 38)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485116(US10934304, Example 37)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485115(US10934304, Example 36)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485114(US10934304, Example 35)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485145(US10934304, Example 66)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485144(US10934304, Example 65)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485143(US10934304, Example 64)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485142(US10934304, Example 63)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485141(US10934304, Example 62)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485140(US10934304, Example 61)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485139(US10934304, Example 60)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485138(US10934304, Example 59)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485137(US10934304, Example 58)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485136(US10934304, Example 57)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485135(US10934304, Example 56)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485134(US10934304, Example 55)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485133(US10934304, Example 54)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485132(US10934304, Example 53)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485131(US10934304, Example 52)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485130(US10934304, Example 51)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485161(US10934304, Example 89)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485160(US10934304, Example 84)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485159(US10934304, Example 82)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM485158(US10934304, Example 81)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

Displayed 1 to 50 (of 88 total ) | Next | Last >>
Jump to: